RARE
FDA Clears ULTRAGENYX (RARE) Gene Therapy Fayuvi for Sanfilippo Syndrome Type A
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with MPS IIIA, a rare inherited disorder.
RARE
Market-moving news on Ultragenyx Pharmaceutical (NASDAQ: RARE): filings, earnings, deals and other events, from REDFILED.
